Bibliography
- LEVER AML: Gene therapy for HIV infection. Br. Med. Bull. (1995) 51(0:149–166.
- WURTMAN RJ: What went right: why is HIV a treatable disease? Nature Med. (1997) 3:714–717.
- CHEN JD, BAT XF, YANG AG et al: Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nature Med. (1997) 3:1110–1116.
- NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene de-livery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263–267.
- ZUFFEREY R, NAGY D, MANDEL RJ et al.: Multiply attenu-ated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol (1997) 15:871–875.
- DONAHUE RE et al.: Reduction in SW replication in rhesus macaques infused with autologous lympho-cytes engineered with antiviral genes. Nature Med. (1998) 4(2):181–186.
- ••One of the first clinical 'trials' where there is preliminary evi-dence of a gene therapy approach improving markers of dis-ease progression, albeit in an SIVmac model.
- WOFFENDIN C et al.: Expression of a protective gene- prolongs survival of T cells in human immunodefi-ciency virus-infected patients. Proc. Natl. Acad. Sci. USA (1996) 93(7) :2889–2894.
- •Another trial using the RevM10 suggesting improved sur-vival of protected lymphocytes in vivo.
- SARVER N, ROSSI J: Gene therapy: a bold direction for 111V-1 treatment. AIDS Res. Human Retroviruses (1993) 9(5) :483–487.
- CARA A et al.: Inhibition of 111V-1 replication by com-bined expression of gag dominant negative mutant and a human ribonuclease on a tightly-controlled 111V-1 inducible vector. Gene Therapy (1998) 5:65–75.
- AGARWAL M, AUSTIN TW, MOREL F et al.: Scaffold at-tachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Vim]. (1998) 72:3720–3728.
- SUN LQ, GERLACH WL, SYMONDS G: Antisense and ribo-zyme strategies for 111V-1 infection. Drug News Perspect (1995) 8(6):325–331.
- •It is likely that these antivirals are being assessed in two trials in Australia.
- YAMADA 0 et al. Conservation of a hairpin ribozyme sequence in111V-1 is required for efficient viral replica-tion. Virology (1996) 22O(2):361–366.
- YU M et al.: In vitro and in vivo characterization of a sec- ond functional hairpin ribozyme against 111V-1. Virol-ogy (1995) 206(1):381–386.
- VERES G et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus Type 1 replication. J. Vim]. (1998) 72 (3) :1894–1901.
- •A useful and exhaustive comparison of antisense inhibitors as compared to RevM10 in primary T-cells as well as T-cell lines.
- ROSENZWEIG M, MARKS DF, HEMPEL D et al.: Transduc-tion of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. (1997) 71:2740–2746.
- LEVYMINTZ P et al.: Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus Type 1 integrase. Vim]. (1996) 70(12) :8821–8832.
- MHASHILKAR AM et al.: Inhibition of 11IV-1 Tat-mediated LTR transactivation and 111V-1 infection by anti-Tat single chain intrabodies. EMBO J. (1995) i4(7):1542–1551.
- FENG Y et al.: 111V-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science (1996) 272 (5263) :872–877.
- POESCHLA E, CORBEAU P, WONG-STAAL F: Develop-ment of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:11395–11399.
- KIM VN et al.: Minimal requirement for a lentivirus vec-tor based on human immunodeficiency virus Type 1.1 Vim]. (1998) 72(1):811–616.
- LEVER AML: Gene therapy in the fight against AIDS. Exp.Opin. Ther. Patents (1996) 6:161–167.